Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $5.3 billion, reflecting a 0.4% increase year-on-year, with New BD growing by 2.5% [5][18] - Adjusted gross margin was 53.4%, down 140 basis points from the prior year, primarily due to tariffs [20] - Adjusted EPS was $2.91, a decrease of 15.2% year-on-year, mainly impacted by tariffs [21] - Free cash flow for the quarter was $548 million, with a conversion rate of 66%, up from 59% in the prior year [22] Business Line Data and Key Metrics Changes - Medical Essentials experienced expected order timing dynamics and volume-based procurement in China, partially offset by share gains in the US [18] - Connected Care delivered mid-single-digit growth, led by high single-digit growth in APM [18] - Biopharma Systems grew low single digits, with double-digit growth in biologics, particularly GLP-1s, offset by lower vaccine demand [19] - Interventional and surgery segments both delivered solid mid-single-digit growth, with strong performance in Advanced Tissue Regeneration [19] Market Data and Key Metrics Changes - The US market showed solid growth in the BD Vacutainer portfolio, while challenges persisted in China due to market dynamics [18] - Alaris performance was slightly ahead of expectations despite a revenue decline due to tough comparisons to the prior year [19] - The Life Sciences segment declined due to US point-of-care headwinds and market dynamics in China [20] Company Strategy and Development Direction - The company is focused on a balanced capital allocation strategy, prioritizing share repurchases and tuck-in M&A in high-growth markets [8][9] - Key trends shaping the future of healthcare include the rise of smart devices, the shift towards lower-cost care settings, and the growth in chronic disease technologies [9][10] - The company aims to enhance its commercial capabilities and operational excellence through its "Excellence Unleashed" strategy, focusing on competing, innovating, and delivering [11][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, with core growth drivers remaining intact [27] - The company anticipates low single-digit revenue growth for New BD in fiscal 2026, with a positive currency impact expected [23] - Management acknowledged known headwinds in 10% of the portfolio but emphasized strong fundamentals in the remaining 90% [33] Other Important Information - The company is set to close a significant transaction with Waters, receiving a $4 billion cash distribution, with plans to allocate $2 billion for share repurchases and $2 billion for debt paydown [8][24] - The company has reduced its manufacturing network by nearly half, enhancing operational efficiency and cost management [16][56] Q&A Session Summary Question: Guidance for Q2 revenue and EPS - Management indicated that Q2 guidance reflects modest timing benefits and that core growth drivers remain intact, with no ramp expected from Q1 to Q2 [27][28] Question: Structural changes affecting mid-single-digit growth - Management confirmed confidence in the portfolio, noting strong performance in high-growth areas despite known headwinds [33] Question: Impact of Alaris and vaccines in China - Management expects Alaris to step up in 2027, with vaccines anticipated to have a smaller revenue impact moving forward [40][42] Question: M&A opportunities under New BD strategy - The company remains focused on tuck-in M&A that is accretive to revenue and EPS, with a robust pipeline in high-growth sectors [78][80] Question: Pricing environment and potential for price premiums - Management noted a stable pricing environment with slight positive pricing expected outside of China, anticipating improvements as VBP dynamics lessen [91]

Becton, Dickinson and Company (NYSE:BDX) Q1 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsJayson Bedford - Managing Director in Equity ResearchPatrick Wood - Managing Director in Equity ResearchRick Wise - Managing DirectorShawn Bevec - Senior Vice President of Investor RelationsTom Polen - Chairman, CEO and PresidentTravis Steed - Managing Director in Equity ResearchVitor Roque - SVP and Interim CFOConference Call ParticipantsJoanne Wuensch - Managing Director and Senior Equity Resea ...

Initial Distribution Launch Marks Transition to Revenue-Generating Operations WESTMINSTER, CALIFORNIA / ACCESS Newswire / February 9, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator, announced today that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order from Advanced Solution, LLC for ViaCLYRâ"¢, Clyra's FDA-cleared wound irrigation solution. The order marks the start of commercial distribution and represents Clyra's transition fro ...

Core Viewpoint - Medical device maker Becton Dickinson has revised its profit forecast for fiscal year 2026, reflecting the impact of the separation and sale of its biosciences and diagnostics unit [1] Group 1 - The company has adjusted its outlook to account for the recent strategic changes involving its biosciences and diagnostics unit [1]

In New York, the Company successfully facilitated an advanced training initiative at the Columbia University Irving Medical Center, led by Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program and Fellowship Director at Columbia University. This high-level collaboration empowered distinguished specialists Dr. Todd Frieze and Dr. Alberto Monreal from Duke Health, to refine techniques in minimally invasive therapies, including Baird Medical´s Microwave Ablation System for the treatment of Ben ...

Core Insights - SeaStar Medical Holding Corporation announced the publication of early post-approval clinical experience of the QUELIMMUNE therapy in Pediatric Nephrology, demonstrating strong survival data and a favorable safety profile [2][3][4] Group 1: Clinical Data and Outcomes - The QUELIMMUNE therapy showed a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90 among the first 21 pediatric patients with Acute Kidney Injury (AKI) and sepsis [4] - The therapy is associated with a 50% reduction in patient mortality at 60 days compared to historical data, consistent with results from prior clinical trials [4][10] - Among patients treated with QUELIMMUNE and extracorporeal membrane oxygenation (ECMO), a 60% survival rate was observed at Day 90 [5] Group 2: Safety Profile - No device-related adverse events or infections were reported in the initial patient cohort, indicating a favorable safety profile for the QUELIMMUNE therapy [4][6] - The absence of immunosuppressive effects further supports the therapy's safety in critically ill pediatric patients [4] Group 3: Regulatory and Research Framework - The SAVE Registry, a post-approval surveillance registry, is designed to collect additional safety and clinical effectiveness data for QUELIMMUNE therapy, initially requiring the enrollment of 300 patients, later reduced to 50 after discussions with the FDA [6][9] - The QUELIMMUNE therapy was approved under a Humanitarian Device Exemption, necessitating participation in the SAVE Registry for real-world data collection [9][14] Group 4: Broader Implications and Adoption - The QUELIMMUNE therapy has been adopted by several nationally recognized children's medical centers in the U.S., indicating growing acceptance and potential for broader application [7] - The therapy aims to address the urgent need for effective treatments for critically ill pediatric patients facing life-threatening conditions due to AKI and sepsis [13][14]

Core Insights - SeaStar Medical Holding Corporation announced positive early post-approval clinical experience for QUELIMMUNE therapy, showing strong survival rates in pediatric patients with Acute Kidney Injury (AKI) and sepsis [1][2][3] Group 1: Clinical Data and Outcomes - The SAVE Registry reported a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90 for pediatric patients treated with QUELIMMUNE therapy [3] - No device-related adverse events or infections were observed in the first 21 patients, indicating a favorable safety profile [3][5] - Among patients treated with QUELIMMUNE and requiring extracorporeal membrane oxygenation (ECMO), a 60% survival rate was noted at Day 90 [4] Group 2: Regulatory and Adoption Insights - The FDA initially required 300 patients for the SAVE Registry but reduced the target to 50 after reviewing data from the first 21 patients [5] - QUELIMMUNE therapy has been adopted by several top-rated children's medical centers across the United States [6] Group 3: Company Background and Product Information - SeaStar Medical focuses on transforming treatments for critically ill patients facing organ failure, with QUELIMMUNE being its first commercial product approved in 2024 [12][13] - The Selective Cytopheretic Device (SCD) therapy aims to neutralize overactive immune cells and mitigate destructive hyperinflammation, with potential applications in various acute and chronic conditions [11]

Core Insights - Stereotaxis has launched a new robotic electrophysiology program at Klinikum Fürth in Germany, marking a significant advancement in surgical robotics for minimally invasive endovascular interventions [1][2]. Company Overview - Stereotaxis is a pioneer and global leader in surgical robotics, focusing on minimally invasive endovascular interventions. The company aims to enhance patient care through robotic precision and safety, while also expanding access to minimally invasive therapies [5]. Technological Advancements - The Genesis Robotic Magnetic Navigation System is being utilized at Klinikum Fürth, establishing a new standard of care for patients with arrhythmias. This advanced technology allows for the successful treatment of a wide range of arrhythmias [2][4]. - The Robotic Magnetic Navigation technology minimizes the need for fluoroscopic confirmation, thereby reducing radiation exposure for both patients and medical staff [4]. Market Impact - The introduction of this technology is expected to significantly benefit patients suffering from arrhythmias, which affect tens of millions globally. Untreated arrhythmias can lead to severe health risks, including stroke, heart failure, and sudden cardiac arrest [4]. Strategic Partnerships - Stereotaxis is collaborating with Klinikum Fürth to enhance access to minimally invasive arrhythmia care in Germany, indicating a strategic move to expand its market presence and support impactful medical practices [5].

Core Viewpoint - A California court has ordered Medtronic to pay Applied Medical nearly $382 million in damages for monopolistic practices in the bipolar electrosurgical devices market [1] Group 1: Lawsuit Details - Applied Medical filed a lawsuit in February 2023, alleging that Medtronic and certain hospital group purchasing organizations (GPOs) had contracts favoring Medtronic as the 'sole source' for advanced bipolar electrosurgical devices, specifically the LigaSure device [2] - The lawsuit claimed that hospitals faced "financial penalties" and other burdens if they circumvented the GPOs' contracts, which restricted their procurement options [3] Group 2: Court Ruling and Implications - A jury in Los Angeles sided with Applied Medical, confirming that Medtronic used restrictive contracts with healthcare providers [3] - Following the verdict, Applied Medical announced plans to seek injunctive relief to prevent Medtronic from enforcing these restrictions [3] Group 3: Industry Impact - Gary Johnson, a representative for Applied Medical, stated that the ruling validates fair competition and could help hospitals access innovation and value by dismantling complex contractual barriers [4] - Applied Medical emphasized that it was unable to compete effectively with its Voyant device due to Medtronic's restrictive practices and bundling strategies [5] - The company also noted that Medtronic's larger business in other surgical products allegedly conditioned discounts on hospitals purchasing Medtronic's bipolar devices, further stifling competition [6]

Core Insights - Inspira Technologies has received official approval from Clalit Health Services for the INSPIRA™ ART100 system, marking a significant commercial advancement for the company [1][4]. Commercial Activation - The approval allows the ART100 to transition from regulatory clearance to active commercial availability within Clalit, which serves approximately 4.9 million members [7]. - Clalit operates 14 major hospitals and over 1,600 clinics, providing access to one of the most sophisticated healthcare supply chains globally [7]. Validation of Clinical Value - The approval follows a rigorous technical and clinical review by the Professional Committee for Medical Equipment, confirming the ART100's safety and efficacy profile [7]. - This validation serves as a powerful reference case for Inspira Technologies as it accelerates commercialization efforts in the U.S. and other global markets [4]. Strategic Positioning - The CEO of Inspira Technologies emphasized that securing vendor status with Clalit is a definitive commercial inflection point, comparable to leading U.S. integrated systems like Kaiser Permanente [3]. - The company views this approval as a foundation for potentially long-term, high-quality revenue [4]. Product Overview - The INSPIRA™ ART100 system is FDA-cleared for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5]. - The company is also developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake and breathing spontaneously [5].